Pt-based drugs: The spotlight will be on proteins

Metallomics

Volumn 6, Issue 3, 2014, Pages 380-395

  Pinato, O ^a   Musetti, C ^a   Sissi, C ^a  

^a Department of Pharmaceutical and Pharmacological Science ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADDUCT FORMATION; EXPERIMENTAL EVIDENCE; MECHANISM OF ACTION; PHARMACOLOGICAL PROFILES; PLATINUM COMPLEXES; PROTEIN ADDUCTS; REACTIVE INTERMEDIATE; RESERVOIR SYSTEMS;

BIOMOLECULES; DNA; METAL COMPLEXES; PLATINUM; PLATINUM ALLOYS; PLATINUM COMPOUNDS; REACTION INTERMEDIATES;

PROTEINS;

CISPLATIN; COPPER PROTEIN; CYSTEINE PROTEINASE; METAL COMPLEX; NUCLEIC ACID BASE; PLATINUM COMPLEX; PLATINUM DERIVATIVE; PROTEIN; ZINC FINGER PROTEIN;

ANTINEOPLASTIC ACTIVITY; CHEMICAL REACTION; CROSS LINKING; DNA ADDUCT; DRUG BIOAVAILABILITY; DRUG INTERACTION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOXICITY; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; MODELS, MOLECULAR; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PROTEINS;

EID: 84896833796     PISSN: 17565901     EISSN: 1756591X     Source Type: Journal    
DOI: 10.1039/c3mt00357d     Document Type: Review

References (83)

1. N. J. Wheate S. Walker G. E. Craig R. Oun The status of platinum anticancer drugs in the clinic and in clinical trials Dalton Trans. 2010 39 8113 8127
2. D. Wang S. J. Lippard Cellular processing of platinum anticancer drugs Nat. Rev. Drug Discovery 2005 4 307 320
3. T. Peters Jr Serum albumin Adv. Protein. Chem. 1985 37 161 245
4. O. Pinato C. Musetti N. P. Farrell C. Sissi Platinum-based drugs and proteins: reactivity and relevance to DNA adduct formation J. Inorg. Biochem. 2013 122 27 37
5. J. J. Liu J. Lu M. J. McKeage Membrane transporters as determinants of the pharmacology of platinum anticancer drugs Curr. Cancer Drug Targets 2012 12 962 986
6. U. Jungwirth C. R. Kowol B. K. Keppler C. G. Hartinger W. Berger P. Heffeter Anticancer activity of metal complexes: involvement of redox processes Antioxid. Redox Signaling 2011 15 1085 1127
7. N. S. Kosower E. M. Kosower The glutathione status of cells Int. Rev. Cytol. 1978 54 109 160
8. E. S. Arner H. Nakamura T. Sasada J. Yodoi A. Holmgren G. Spyrou Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex Free Radicals Biol. Med. 2001 31 1170 1178
9. X. Wang Z. Guo Targeting and delivery of platinum-based anticancer drugs Chem. Soc. Rev. 2013 42 202 224
10. J. S. Butler P. J. Sadler Targeted delivery of platinum-based anticancer complexes Curr. Opin. Chem. Biol. 2013 17 175 188
11. S. Huo S. Shen D. Liu T. Shi Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(iv) anticancer prodrug and model complex: kinetic and mechanistic studies J. Phys. Chem. B 2012 116 6522 6528
12. H. Xiao R. Qi S. Liu X. Hu T. Duan Y. Zheng Y. Huang X. Jing Biodegradable polymer-cisplatin(iv) conjugate as a pro-drug of cisplatin(II) Biomaterials 2011 32 7732 7739
13. H. Xiao H. Song Y. Zhang R. Qi R. Wang Z. Xie Y. Huang Y. Li Y. Wu X. Jing The use of polymeric platinum(iv) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy Biomaterials 2012 33 8657 8669
14. M. Sooriyaarachchi A. Narendran J. Gailer The effect of sodium thiosulfate on the metabolism of cis-platin in human plasma in vitro Metallomics 2012 4 960 967
15. T. M. Harned O. Kalous A. Neuwelt J. Loera L. Ji P. Iovine R. Sposto E. A. Neuwelt C. P. Reynolds Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity Clin. Cancer Res. 2008 14 533 540
16. F. H. Hausheer H. Kochat A. R. Parker D. Ding S. Yao S. E. Hamilton P. N. Petluru B. D. Leverett S. H. Bain J. D. Saxe New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent Cancer Chemother. Pharmacol. 2003 52 suppl 1 S3 S15
17. A. R. Parker P. N. Petluru M. Wu M. Zhao H. Kochat F. H. Hausheer BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro Mol. Cancer Ther. 2010 9 2558 2567
18. B. T. Benedetti S. Quintal N. P. Farrell Modulation of drug activation profiles through carboxylate ligand modification in cytotoxic trans-platinum planar amine compounds Dalton Trans. 2011 40 10983 10988
19. C. Gabbiani A. Casini G. Mastrobuoni N. Kirshenbaum O. Moshel G. Pieraccini G. Moneti L. Messori D. Gibson Peculiar mechanistic and structural features of the carboplatin-cytochrome c system revealed by ESI-MS analysis JBIC, J. Biol. Inorg. Chem. 2008 13 755 764
20. T. Karasawa M. Sibrian-Vazquez R. M. Strongin P. S. Steyger Identification of cisplatin-binding proteins using agarose conjugates of platinum compounds PLoS One 2013 8 e66220
21. S. M. Aris N. P. Farrell Towards antitumor active trans-platinum compounds Eur. J. Org. Chem. 2009 19 1293 1302
22. C. Li R. Huang Y. Ding E. Sletten F. Arnesano M. Losacco G. Natile Y. Liu Effect of Thioethers on DNA Platination by trans-Platinum Complexes Inorg. Chem. 2011 50 8168 8176
23. C. Li Z. Li E. Sletten F. Arnesano M. Losacco G. Natile Y. Liu Methionine Can Favor DNA Platination by trans-Coordinated Platinum Antitumor Drugs Angew. Chem., Int. Ed. 2009 48 8497 8500
24. C. Musetti A. A. Nazarov N. P. Farrell C. Sissi DNA Reactivity Profile of trans-Platinum Planar Amine Derivatives ChemMedChem 2011 6 1283 1290
25. M. Sooriyaarachchi A. Narendran J. Gailer Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro Metallomics 2011 3 49 55
26. R. D. Sandlin C. J. Whelan M. S. Bradley K. M. Williams Effects of amine ligand bulk and hydrogen bonding on the rate of reaction of platinum(II) diamine complexes with key nucleotide and amino acid residues Inorg. Chim. Acta 2012 391 135 140
27. S. D. Brown K. D. Trotter O. B. Sutcliffe J. A. Plumb B. Waddell N. E. Briggs N. J. Wheate Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity Dalton Trans. 2012 41 11330 11339
28. N. Margiotta N. Denora R. Ostuni V. Laquintana A. Anderson S. W. Johnson G. Trapani G. Natile Platinum(II) complexes with bioactive carrier ligands having high affinity for the translocator protein J. Med. Chem. 2010 53 5144 5154
29. C. Mugge E. Micheucci F. Boscaro C. Gabbiani L. Messori W. Weigand Reactions of metallodrugs with proteins: selective binding of phosphane-based platinum(II) dichlorides to horse heart cytochrome c probed by ESI MS coupled to enzymatic cleavage Metallomics 2011 3 987 990
30. C. Mugge C. Rothenburger A. Beyer H. Gorls C. Gabbiani A. Casini E. Michelucci I. Landini S. Nobili E. Mini L. Messori W. Weigand Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors Dalton Trans. 2011 40 2006 2016
31. K. G. Samper C. Vicente V. Rodriguez S. Atrian N. Cutillas M. Capdevila J. Ruiz O. Palacios Studying the interactions of a platinum(II) 9-aminoacridine complex with proteins and oligonucleotides by ESI-TOF MS Dalton Trans. 2012 41 300 306
32. S. Cerri V. M. Piccolini G. Santin M. G. Bottone S. A. De Pascali D. Migoni P. Iadarola F. P. Fanizzi G. Bernocchi The developmental neurotoxicity study of platinum compounds. Effects of cisplatin versus a novel Pt(II) complex on rat cerebellum Neurotoxicol. Teratol. 2011 33 273 281
33. M. Frezza Q. P. Dou Y. Xiao H. Samouei M. Rashidi F. Samari B. Hemmateenejad In vitro and in vivo antitumor activities and DNA binding mode of five coordinated cyclometalated organoplatinum(II) complexes containing biphosphine ligands J. Med. Chem. 2011 54 6166 6176
34. F. Samari B. Hemmateenejad M. Shamsipur M. Rashidi H. Samouei Affinity of two novel five-coordinated anticancer Pt(II) complexes to human and bovine serum albumins: a spectroscopic approach Inorg. Chem. 2012 51 3454 3464
35. R. Yousefi S. Aghevlian F. Mokhtari H. Samouei M. Rashidi S. M. Nabavizadeh Z. Tavaf Z. Pouryasin A. Niazi R. Faghihi M. M. Papari The anticancer activity and HSA binding properties of the structurally related platinum (II) complexes Appl. Biochem. Biotechnol. 2012 167 861 872
36. B. T. Benedetti E. J. Peterson P. Kabolizadeh A. Martínez R. Kipping N. P. Farrell Effects of Noncovalent Platinum Drug-Protein Interactions on Drug Efficacy: Use of Fluorescent Conjugates as Probes for Drug Metabolism Mol. Pharmaceutics 2011 8 940 948
37. R. Olivova J. Kasparkova O. Vrana M. Vojtiskova T. Suchankova O. Novakova W. He Z. Guo V. Brabec Unique DNA binding mode of antitumor trinuclear tridentate platinum(II) compound Mol. Pharmaceutics 2011 8 2368 2378
38. Y. Wang X. Wang J. Wang Y. Zhao W. He Z. Guo Noncovalent interactions between a trinuclear monofunctional platinum complex and human serum albumin Inorg. Chem. 2011 50 12661 12668
39. A. Casini G. Mastrobuoni C. Temperini C. Gabbiani S. Francese G. Moneti C. T. Supuran A. Scozzafava L. Messori ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme Chem. Commun. 2007 156 158
40. V. Calderone A. Casini S. Mangani L. Messori P. L. Orioli Structural Investigation of Cisplatin-Protein Interactions: Selective Platination of His19 in a Cuprozinc Superoxide Dismutase Angew. Chem., Int. Ed. 2006 45 1267 1269
41. A. Casini A. Guerri C. Gabbiani L. Messori Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: New insights from X-ray diffraction and mass spectrometry studies J. Inorg. Biochem. 2008 102 995 1006
42. S. W. Tanley A. M. Schreurs L. M. Kroon-Batenburg J. Meredith R. Prendergast D. Walsh P. Bryant C. Levy J. R. Helliwell Structural studies of the effect that dimethyl sulfoxide (DMSO) has on cisplatin and carboplatin binding to histidine in a protein Acta Crystallogr., Sect. D: Biol. Crystallogr. 2012 68 601 612
43. S. J. Fischer L. M. Benson A. Fauq S. Naylor A. J. Windebank Cisplatin and dimethyl sulfoxide react to form an adducted compound with reduced cytotoxicity and neurotoxicity Neurotoxicology 2008 29 444 452
44. S. W. Tanley A. M. Schreurs L. M. Kroon-Batenburg J. R. Helliwell Room-temperature X-ray diffraction studies of cisplatin and carboplatin binding to His15 of HEWL after prolonged chemical exposure Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun. 2012 68 1300 1306
45. E. Ortega-Carrasco F. P. Cossio A. Lledos J. D. Marechal Computational insights on the possibility of tri-coordinated cisplatinated adducts with protein models J. Inorg. Biochem. 2012 117 230 236
46. S. Prast-Nielsen M. Cebula I. Pader E. S. Arner Noble metal targeting of thioredoxin reductase-covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin Free Radicals Biol. Med. 2010 49 1765 1778
47. Y. C. Lo T. P. Ko W. C. Su T. L. Su A. H. Wang Terpyridine-platinum(II) complexes are effective inhibitors of mammalian topoisomerases and human thioredoxin reductase 1 J. Inorg. Biochem. 2009 103 1082 1092
48. Y. C. Lo W. C. Su T. P. Ko N. C. Wang A. H. Wang Terpyridine platinum(II) complexes inhibit cysteine proteases by binding to active-site cysteine J. Biomol. Struct. Dyn. 2011 29 267 282
49. M. E. Palm-Espling M. S. Niemiec P. Wittung-Stafshede Role of metal in folding and stability of copper proteins in vitro Biochim. Biophys. Acta 2012 1823 1594 1603
50. A. K. Boal A. C. Rosenzweig Crystal structures of cisplatin bound to a human copper chaperone J. Am. Chem. Soc. 2009 131 14196 14197
51. R. Safaei M. H. Maktabi B. G. Blair C. A. Larson S. B. Howell Effects of the loss of Atox1 on the cellular pharmacology of cisplatin J. Inorg. Biochem. 2009 103 333 341
52. M. E. Palm C. F. Weise C. Lundin G. Wingsle Y. Nygren E. Bjorn P. Naredi M. Wolf-Watz P. Wittung-Stafshede Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro Proc. Natl. Acad. Sci. U. S. A. 2011 108 6951 6956
53. M. E. Palm-Espling P. Wittung-Stafshede Reaction of platinum anticancer drugs and drug derivatives with a copper transporting protein, Atox1 Biochem. Pharmacol. 2012 83 874 881
54. F. Arnesano L. Banci I. Bertini I. C. Felli M. Losacco G. Natile Probing the interaction of cisplatin with the human copper chaperone Atox1 by solution and in-cell NMR spectroscopy J. Am. Chem. Soc. 2011 133 18361 18369
55. M. P. McLaughlin T. H. Darrah P. L. Holland Palladium(II) and platinum(II) bind strongly to an engineered blue copper protein Inorg. Chem. 2011 50 11294 11296
56. P. Tassone M. T. Di Martino M. Ventura A. Pietragalla I. Cucinotto T. Calimeri A. Bulotta P. Neri M. Caraglia P. Tagliaferri Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo Cancer Biol. Ther. 2009 8 648 653
57. A. Atipairin B. Canyuk A. Ratanaphan Cisplatin affects the conformation of apo form, not holo form, of BRCA1 RING finger domain and confers thermal stability Chem. Biodiversity 2010 7 1949 1967
58. A. Atipairin B. Canyuk A. Ratanaphan The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs Breast Cancer Res. Treat. 2011 126 203 209
59. D. A. Sartori B. Miller U. Biebach N. Farrell Modulation of the chemical and biological properties of trans platinum complexes: monofunctional platinum complexes containing one nucleobase as potential antiviral chemotypes JBIC, J. Biol. Inorg. Chem. 2000 5 575 583
60. S. Quintal A. Viegas S. Erhardt E. J. Cabrita N. P. Farrell Platinated DNA affects zinc finger conformation. Interaction of a platinated single-stranded oligonucleotide and the C-terminal zinc finger of nucleocapsid protein HIVNCp7 Biochemistry 2012 51 1752 1761
61. E. Moreno-Gordaliza B. Canas M. A. Palacios M. M. Gomez-Gomez Top-down mass spectrometric approach for the full characterization of insulin-cisplatin adducts Anal. Chem. 2009 81 3507 3516
62. E. Moreno-Gordaliza B. Canas M. A. Palacios M. M. Gomez-Gomez Novel insights into the bottom-up mass spectrometry proteomics approach for the characterization of Pt-binding proteins: the insulin-cisplatin case study Analyst 2010 135 1288 1298
63. C. Moller R. R. Sprenger S. Sturup P. Hojrup Determination of the binding sites for oxaliplatin on insulin using mass spectrometry-based approaches Anal. Bioanal. Chem. 2011 401 1619 1629
64. H. Li T. Y. Lin S. L. Van Orden Y. Zhao M. P. Barrow A. M. Pizarro Y. Qi P. J. Sadler P. B. O'Connor Use of top-down and bottom-up Fourier transform ion cyclotron resonance mass spectrometry for mapping calmodulin sites modified by platinum anticancer drugs Anal. Chem. 2011 83 9507 9515
65. H. Li S. A. Wells J. E. Jimenez-Roldan R. A. Romer Y. Zhao P. J. Sadler P. B. O'Connor Protein flexibility is key to cisplatin crosslinking in calmodulin Protein Sci. 2012 21 1269 1279
66. E. Moreno-Gordaliza B. Canas M. A. Palacios M. M. Gomez-Gomez Characterization of Pt-protein complexes by nHPLC-ESI-LTQ MS/MS using a gel-based bottom-up approach Talanta 2012 88 599 608
67. T. T. Nguyen J. Ostergaard S. Sturup B. Gammelgaard Metallomics in drug development: characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS Anal. Bioanal. Chem. 2013 405 1845 1854
68. J. P. Williams H. I. Phillips I. Campuzano P. J. Sadler Shape changes induced by N-terminal platination of ubiquitin by cisplatin J. Am. Soc. Mass Spectrom. 2010 21 1097 1106
69. H. Li Y. Zhao H. I. Phillips Y. Qi T. Y. Lin P. J. Sadler P. B. O'Connor Mass spectrometry evidence for cisplatin as a protein cross-linking reagent Anal. Chem. 2011 83 5369 5376
70. K. Shrivas K. Agrawal H. F. Wu Application of platinum nanoparticles as affinity probe and matrix for direct analysis of small biomolecules and microwave digested proteins using matrix-assisted laser desorption/ionization mass spectrometry Analyst 2011 136 2852 2857
71. K. Isozaki K. Ogata Y. Haga D. Sasano T. Ogawa H. Kurata M. Nakamura T. Naota H. Takaya Metal array fabrication through self-assembly of Pt-complex-bound amino acids Chem. Commun. 2012 48 3936 3938
72. J. Gajdzik J. Lenz H. Natter R. Hempelmann G. W. Kohring F. Giffhorn M. Manolova D. M. Kolb Enzyme immobilisation on self-organised nanopatterned electrode surfaces Phys. Chem. Chem. Phys. 2010 12 12604 12607
73. M. C. Yeung K. M. Wong Y. K. Tsang V. W. Yam Aptamer-induced self-assembly of a NIR-emissive platinum(II) terpyridyl complex for label- and immobilization-free detection of lysozyme and thrombin Chem. Commun. 2010 46 7709 7711
74. 2+: a new specific peptide cleavage site Inorg. Chem. 2010 49 8148 8154
75. D. Valesin C. Gabbiani L. Mesosri Metal compounds as inhibitors of b-amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer's disease Coord. Chem. Rev. 2012 256 2357 2366
76. A. D. Watt V. L. Villemagne K. J. Barnham Metals, membranes, and amyloid-beta oligomers: key pieces in the Alzheimer's disease puzzle? J. Alzheimer's Dis. 2013 33 suppl 1 S283 S293
77. K. J. Barnham V. B. Kenche G. D. Ciccotosto D. P. Smith D. J. Tew X. Liu K. Perez G. A. Cranston T. J. Johanssen I. Volitakis A. I. Bush C. L. Masters A. R. White J. P. Smith R. A. Cherny R. Cappai Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease Proc. Natl. Acad. Sci. U. S. A. 2008 105 6813 6818
78. X. Ren X. Pan Z. Zhang D. Wang X. Lu Y. Li D. Wen H. Long J. Luo Y. Feng X. Zhuang F. Zhang J. Liu F. Leng X. Lang Y. Bai M. She Z. Tu J. Pan K. Ding Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib J. Med. Chem. 2013 56 879 894
79. I. Sasaki C. Bijani S. Ladeira V. Bourdon P. Faller C. Hureau Interference of a new cyclometallated Pt compound with Cu binding to amyloid-beta peptide Dalton Trans. 2012 41 6404 6407
80. G. Ma F. Huang X. Pu L. Jia T. Jiang L. Li Y. Liu Identification of [PtCl2(phen)] binding modes in amyloid-beta peptide and the mechanism of aggregation inhibition Chemistry 2011 17 11657 11666
81. V. A. Streltsov V. Chandana Epa S. A. James Q. I. Churches J. M. Caine V. B. Kenche K. J. Barnham Structural insights into the interaction of platinum-based inhibitors with the Alzheimer's disease amyloid-beta peptide Chem. Commun. 2013 49 11364 11366
82. V. B. Kenche L. W. Hung K. Perez I. Volitakes G. Ciccotosto J. Kwok N. Critch N. Sherratt M. Cortes V. Lal C. L. Masters K. Murakami R. Cappai P. A. Adlard K. J. Barnham Development of a platinum complex as an anti-amyloid agent for the therapy of Alzheimer's disease Angew. Chem. 2013 52 3374 3378
83. F. Collin I. Sasaki H. Eury P. Faller C. Hureau Pt(II) compounds interplay with Cu(II) and Zn(II) coordination to the amyloid-beta peptide has metal specific consequences on deleterious processes associated to Alzheimer's disease Chem. Commun. 2013 49 2130 2132